Company intelligence / Profile preview

LiPlasome Pharma

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

LiPlasome Pharma has developed a proprietary liposomal drug delivery platform designed to encapsulate chemotherapy drugs, such as cisplatin, enabling them to dissolve specifically in and around cancerous tissues. This approach aims to increase efficacy while reducing side effects by sparing healthy cells. The company’s lead candidate, LiplaCis—a liposomal formulation of cisplatin—is currently in Phase 1 clinical trials.[3]

Therapeutic areas: Oncology
Modalities: Liposomal formulations (liposome-based drug delivery)ProdrugsChemotherapy agents (notably cisplatin reformulations)
Industry: Biotech

Drug pipeline

3 assets

dovitinib

NDA

Indications: Renal cell carcinoma

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on LiPlasome Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiPlasome Pharma.

Explore the full profile